Overview

A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)

Status:
Completed

Trial end date:
2012-06-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to assess the safety and pharmacokinetics of linifanib, and identify tolerable dose of linifanib (ABT-869) in combination with carboplatin and paclitaxel in Japanese subjects with advanced or metastatic non-small cell lung cancer (NSCLC). Secondary objective is to obtain a preliminary efficacy of anti-tumor activity in the subjects as first-line treatment.

Phase:

Phase 1

Details

Lead Sponsor:

Abbott
AbbVie

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel